SFGP
REGN icon

Stonebridge Financial Group (Pennsylvania)’s Regeneron Pharmaceuticals REGN Stock Holding History

Stonebridge Financial Group (Pennsylvania)’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18
Closed -$11.4K – 779
2025
Q1 		$11.4K Buy
18
+1
+6% +$688 ﹤0.01% 573
2024
Q4 		$12.1K Buy
+17
New +$14.3K ﹤0.01% 567

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Stonebridge Financial Group (Pennsylvania)'s REGN Position: Q2 2025 in Review

Stonebridge Financial Group (Pennsylvania) sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 18 shares — an estimated $11.4K sold.

Stonebridge Financial Group (Pennsylvania) first reported a position in REGN in Q4 2024 and held it in 2 quarters. The position peaked at $12.1K in Q4 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • Stonebridge Financial Group (Pennsylvania) reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Stonebridge Financial Group (Pennsylvania) sold 18 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $11.4K.
  • Stonebridge Financial Group (Pennsylvania) first reported a position in Regeneron Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Stonebridge Financial Group (Pennsylvania)'s Regeneron Pharmaceuticals position peaked at $12.1K in Q4 2024.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Stonebridge Financial Group (Pennsylvania)'s 13F filing for Q2 2025, filed 24 Jul 2025.